Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 6/20 | 0.40 |
| ▸ | HTR6 | P50406 | 9/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21096678 | 0.95 | MAP3K14 (0.44) | MAP3K14HTR6ADORA2AADORA1MTOR | |
| SCHEMBL21096808 | 0.85 | MAP3K14 (0.46) | MAP3K14ADORA2AADORA1MTOR | |
| SCHEMBL16205347 | 0.83 | MAP3K14 (0.43) | MAP3K14HTR6 | |
| SCHEMBL21096679 | 0.82 | MAP3K14 (0.39) | MAP3K14ADORA2AADORA1MTOR | |
| SCHEMBL21096681 | 0.82 | ACVR1 (0.35) | HTR6ADORA2A | |
| SCHEMBL21097146 | 0.81 | ADORA2A (0.37) | MAP3K14ADORA2AADORA1MTOR | |
| SCHEMBL21096798 | 0.81 | ADORA2A (0.38) | MAP3K14ADORA2AADORA1MTOR | |
| SCHEMBL21096536 | 0.79 | MAP3K14 (0.34) | MAP3K14ADORA2AADORA1 | |
| SCHEMBL16205343 | 0.78 | MAP3K14 (0.47) | MAP3K14HTR6MTOR | |
| SCHEMBL21096789 | 0.77 | ADORA2B (0.35) | ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10323045-B2 | Thienopyrimidine derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2019-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10323045-B2 | Thienopyrimidine derivatives as NIK inhibitors | MAP3K14, MAP3K15, MAP3K12 | MAP3K14 1/4885HTR6 4475/4885ADORA2A 4258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.